NCT06175078Not yet recruiting
Three-Dimensional Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses
Investigation of Three-Dimensional Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses
Source: ClinicalTrials.gov · Last updated 27 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of the study is to test the hypothesis that quantitative ultrasound techniques including spectroscopy may be used as a non-invasive biomarker for characterization of suspected breast cancers. The main goal is to select and identify an optimal set of quantitative ultrasound parameters that can be used, non-invasively, to characterize suspected breast cancers, as identified based on the histopathology reports on core biopsy specimens, surgery reports, or radiology reports. Primary endpoint will correlate quantitative ultrasound parameters to the histopathological properties, as determined from pathology reports on core biopsy specimens, surgery reports, or radiology reports. The secondary endpoint in this study will include correlating the results of ultrasound-based breast cancer characterization with 2 and 5-years clinical outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 8 Dec 2023
- Start date
- Apr 2024
- Primary completion date
- Apr 2026
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Diseases
- Childhood cancers
- NCT number
- NCT06175078
What you commit to
- Study type: Observational
- Planned participants: 200
- From Apr 2024 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering in the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration.
- Receiving any other investigational agents.
Other illness
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
Who the study is looking for
- Women or men with suspected breast cancer
- Patients should have the ability to understand and the willingness to sign a written informed consent document.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Health Sciences Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.